

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form 8-K  
July 17, 2006

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

July 11, 2006

(Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

Michigan  
(State or other jurisdiction of  
incorporation)

0-24676  
(Commission file number)

38-2505723  
(I.R.S. employer  
identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

(313) 871-8400

(Registrant's telephone number, including area code)

# Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 8-K

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

## Item 1.01. Entry into a Material Definitive Agreement.

On July 11, 2006, the Compensation Committee of the Board of Directors of registrant approved a 4% increase to the base salary of the Chief Executive Officer and a bonus of 75% of his target bonus (pursuant to his employment agreement) of up to 50% of his base salary. The independent members of the Compensation Committee also awarded the CEO with an option for 40,000 shares of the Company's common stock at the fair market value of the common stock on the date of grant. Pursuant to delegated authority, the CEO approved an increase in the base salaries of, and bonuses for the Senior Vice President - Technical and the Vice President - Sales and Marketing, as set forth below. The discretionary bonuses were made based on sales revenue performance.

| <u>Name</u>       | <u>Title</u>         | Fiscal 2007   | Fiscal 2006              |
|-------------------|----------------------|---------------|--------------------------|
|                   |                      | <u>Salary</u> | <u>Performance Bonus</u> |
| Daniel H. Movens  | CEO                  | \$405,600     | \$146,250                |
| Robert Kurkiewicz | Sr. V.P. - Technical | \$156,818     | \$ 24,512                |
| Gurpartap Singh   | V.P. - Sales &       | \$186,030     | \$ 39,488                |
| Sachdeva          | Marketing            |               |                          |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARACO PHARMACEUTICAL LABORATORIES, LTD.**

Date: July 17, 2006

By: /s/ Daniel H. Movens  
Daniel H. Movens

Chief Executive Officer

---